Sign in Subscribe
Cancer

Canine Cancer Models Offer Insights into Human Cancer Etiology and Therapy

Strategic Insights

— 1 min read

Researchers in the United States have found that spontaneous tumors in dogs can serve as unique models to study human cancer etiology and therapy. The study focused on the role of the p53 gene, commonly mutated in human cancers, in dog tumorigenesis. The researchers discovered that canine p53 is accumulated and capable of inducing its target genes, MDM2 and p21, upon exposure to DNA damage agents or MDM2 inhibitor nutlin-3. Furthermore, they found that canine tumor cells are sensitive to DNA damage agents and nutlin-3 in a p53-dependent manner.

Key Takeaways:

  • The p53 gene is commonly mutated in human cancers and is found to be altered in dog cancers.
  • Canine p53 is accumulated and capable of inducing its target genes, MDM2 and p21, upon exposure to DNA damage agents or MDM2 inhibitor nutlin-3.
  • Canine tumor cells are sensitive to DNA damage agents and nutlin-3 in a p53-dependent manner.
  • Canine p63 and p73 are up-regulated by DNA damage agents.
  • Colony formation assay showed that canine tumor cells are sensitive to DNA damage agents and nutlin-3.
  • Multiple canine p21 mutants were generated, and amino acids 129 to 142 are required for the expression of two p21 isoforms.
  • Amino acid 139 is one of the key determinants for the expression of two p21 isoforms.
  • The full-length human p21 cDNA expresses one polypeptide, and amino acid 139 plays a similar role as in canine p21 for various migration patterns.

Statistics:

  • 67-78: The page numbers of the study published in Molecular Cancer Research.
  • 2009: The year the study was published.
  • 1: The issue number of the study published.
  • 139: Amino acid that plays a key role in the expression of two p21 isoforms.
  • 129-142: The amino acid sequence required for the expression of two p21 isoforms.

Sources:

  • Zhang, J., et al. (2009). Establishment of a Dog Model for the p53 Family Pathway and Identification of a Novel Isoform of p21 Cyclin-Dependent Kinase Inhibitor. Molecular Cancer Research, 7(1), 67-78.
  • American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA. (Publisher contact information for the journal Molecular Cancer Research.)
  • X.B. Chen, University of California, Center Comprehensive Cancer, Tupper 2128, Davis, CA 95616, USA. (Contact information for additional information.)
  • Cancer Weekly editors, staff, and other reports. (Original article prepared by Cancer Weekly editors from staff and other reports.)
  • NewsRx.com. (Copyright holder of the article.)

Read more